



UNIVERSITY OF LEEDS

This is a repository copy of *Changes in Patient-reported Swallow Function in the Long Term After Chemoradiotherapy for Oropharyngeal Carcinoma*.

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/153236/>

Version: Supplemental Material

Article:

Martin, A, Murray, L orcid.org/0000-0003-0658-6455, Sethugavalar, B et al. (4 more authors) (2018) Changes in Patient-reported Swallow Function in the Long Term After Chemoradiotherapy for Oropharyngeal Carcinoma. *Clinical Oncology*, 30 (12). pp. 756-763. ISSN 0936-6555

<https://doi.org/10.1016/j.clon.2018.06.013>

© 2018, The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Table 1: Patient, tumour and treatment details

		N=52
<i>Age (Mean, range)</i>		56 (36-69)
<i>Sex</i>		
	Male	42 (81%)
	Female	10 (19%)
<i>WHO PS</i>		
	0	36 (69%)
	1	5 (10%)
	Not recorded	11 (21%)
<i>Smoking</i>		
	Never	20 (38 %)
	Ex	24 (46%)
	Current	5 (10%)
	Not recorded	3 (6%)
<i>Oropharynx subsite</i>		
	Tonsil	31 (60%)
	BOT	21 (40%)
<i>T stage</i>		
	T1	8 (15%)
	T2	29 (56%)
	T3	4 (8%)
	T4	11 (21%)
<i>Nodal stage</i>		
	N0	4(8%)
	N1	6 (12%)
	N2a	4 (8%)
	N2b	28 (54%)
	N2c	9 (17%)
	N3	1 (2%)
<i>Induction chemotherapy</i>		
	None	40 (77%)
	TPF	10 (19%)
	PF	2 (4%)
<i>Radiotherapy dose</i>		
	65Gy in 30 fractions	3 (6%)
	70Gy in 35 fractions	49 (94%)
<i>Mean contralateral parotid dose (range)/Gy</i>		37 (21-57)
<i>Concurrent chemotherapy</i>		
	Cisplatin	46 (88%)
	Carboplatin	6 (12%)
<i>No. of concurrent chemotherapy cycles</i>		

1	9 (17%)
2	41 (79%)
3	2 (4%)
<i>Pre-treatment oral intake</i>	
NBM	0 (0%)
Sips	0 (0%)
Pureed	1 (2%)
Soft	5 (10%)
Normal	39 (75%)
Not recorded	7 (13%)

Abbreviations: WHO PS=World Health Organisation performance status; BOT=base of tongue; TPF=docetaxel, cisplatin, 5-fluorouracil; PF=cisplatin, 5-fluorouracil; NBM=nil by mouth

Table 2: Summary of MDADI scores for 1st and 2nd questionnaires, n=52. First MDADI administered >24 months post-treatment (median 34 months), and second MDADI administered 30 months later (median 64 months post-treatment). Significant values with $p < 0.05$ indicated in bold.

MDADI	1st questionnaire/ Mean (SD)	2nd questionnaire/ Mean (SD)
Composite	64.0 (16.3)	68.0 (19.3)
Global	62.3 (26.5)	68.9 (26.7)
Emotional	66.5 (18.9)	70.3 (21.6)
Functional	68.2 (19.0)	72.3 (21.5)
Physical	59.7 (14.5)	63.2 (18.6)

Table 3: Summary of change in MDADI scores between 1st and 2nd questionnaires (n=52). Increase of ≥ 10 points defined as clinically significant improvement in patient reported swallow function, decrease of ≥ 10 points defined as clinical deterioration, and $< \pm 10$ points defined as clinically stable.

MDADI	Clinical deterioration)	Clinically stable	Clinical improvement
	Decrease ≥ 10 points (%)	Change $< \pm 10$ points (%)	Increase ≥ 10 points (%)
Composite	6 (12)	29 (56)	17 (33)
Global	6 (12)	26 (50)	20 (38)
Emotional	10 (19)	20 (38)	22 (42)
Functional	12 (23)	20 (38)	20 (38)
Physical	15 (29)	28 (54)	9 (17)

Table 4: Summary of associations between patient/tumour/treatment factors and composite MDADI scores on first and second questionnaire. Significant values with $p < 0.05$ indicated in bold.

Variable	First questionnaire/ p value	Second questionnaire/ p value
Gender *	0.472	0.295
Age ^s	0.449	0.679
Contralateral parotid dose ^s	0.105	0.231
Prophylactic gastrostomy *	0.078	0.044
Induction chemotherapy *	0.394	0.272
Number of cycles of concurrent chemotherapy **	0.270	0.161
T stage **	0.570	0.396
Pre-treatment diet **	0.048	0.029
Enteral feeding by any route *	0.352	0.375

* = independent t test, ^s = Pearson's correlation, ** = Spearman's rho